Cargando…
Natural Products for the Treatment of Post-stroke Depression
Post-stroke depression (PSD) is the most frequent and important neuropsychiatric consequence of stroke. It is strongly associated with exacerbated deterioration of functional recovery, physical and cognitive recoveries, and quality of life. However, its mechanism is remarkably complicated, including...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196125/ https://www.ncbi.nlm.nih.gov/pubmed/35712727 http://dx.doi.org/10.3389/fphar.2022.918531 |
_version_ | 1784727114072719360 |
---|---|
author | Fang, Chaoyou Zhang, Zeyu Xu, Houshi Liu, Yibo Wang, Xiaoyu Yuan, Ling Xu, Yuanzhi Zhu, Zhengyang Zhang, Anke Shao, Anwen Lou, Meiqing |
author_facet | Fang, Chaoyou Zhang, Zeyu Xu, Houshi Liu, Yibo Wang, Xiaoyu Yuan, Ling Xu, Yuanzhi Zhu, Zhengyang Zhang, Anke Shao, Anwen Lou, Meiqing |
author_sort | Fang, Chaoyou |
collection | PubMed |
description | Post-stroke depression (PSD) is the most frequent and important neuropsychiatric consequence of stroke. It is strongly associated with exacerbated deterioration of functional recovery, physical and cognitive recoveries, and quality of life. However, its mechanism is remarkably complicated, including the neurotransmitters hypothesis (which consists of a monoaminergic hypothesis and glutamate-mediated excitotoxicity hypothesis), inflammation hypothesis, dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, and neurotrophic hypothesis and neuroplasticity. So far, the underlying pathogenesis of PSD has not been clearly defined yet. At present, selective serotonin reuptake inhibitors (SSRIs) have been used as the first-line drugs to treat patients with PSD. Additionally, more than SSRIs, a majority of the current antidepressants complied with multiple side effects, which limits their clinical application. Currently, a wide variety of studies revealed the therapeutic potential of natural products in the management of several diseases, especially PSD, with minor side effects. Accordingly, in our present review, we aim to summarize the therapeutic targets of these compounds and their potential role in-clinic therapy for patients with PSD. |
format | Online Article Text |
id | pubmed-9196125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91961252022-06-15 Natural Products for the Treatment of Post-stroke Depression Fang, Chaoyou Zhang, Zeyu Xu, Houshi Liu, Yibo Wang, Xiaoyu Yuan, Ling Xu, Yuanzhi Zhu, Zhengyang Zhang, Anke Shao, Anwen Lou, Meiqing Front Pharmacol Pharmacology Post-stroke depression (PSD) is the most frequent and important neuropsychiatric consequence of stroke. It is strongly associated with exacerbated deterioration of functional recovery, physical and cognitive recoveries, and quality of life. However, its mechanism is remarkably complicated, including the neurotransmitters hypothesis (which consists of a monoaminergic hypothesis and glutamate-mediated excitotoxicity hypothesis), inflammation hypothesis, dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, and neurotrophic hypothesis and neuroplasticity. So far, the underlying pathogenesis of PSD has not been clearly defined yet. At present, selective serotonin reuptake inhibitors (SSRIs) have been used as the first-line drugs to treat patients with PSD. Additionally, more than SSRIs, a majority of the current antidepressants complied with multiple side effects, which limits their clinical application. Currently, a wide variety of studies revealed the therapeutic potential of natural products in the management of several diseases, especially PSD, with minor side effects. Accordingly, in our present review, we aim to summarize the therapeutic targets of these compounds and their potential role in-clinic therapy for patients with PSD. Frontiers Media S.A. 2022-05-30 /pmc/articles/PMC9196125/ /pubmed/35712727 http://dx.doi.org/10.3389/fphar.2022.918531 Text en Copyright © 2022 Fang, Zhang, Xu, Liu, Wang, Yuan, Xu, Zhu, Zhang, Shao and Lou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Fang, Chaoyou Zhang, Zeyu Xu, Houshi Liu, Yibo Wang, Xiaoyu Yuan, Ling Xu, Yuanzhi Zhu, Zhengyang Zhang, Anke Shao, Anwen Lou, Meiqing Natural Products for the Treatment of Post-stroke Depression |
title | Natural Products for the Treatment of Post-stroke Depression |
title_full | Natural Products for the Treatment of Post-stroke Depression |
title_fullStr | Natural Products for the Treatment of Post-stroke Depression |
title_full_unstemmed | Natural Products for the Treatment of Post-stroke Depression |
title_short | Natural Products for the Treatment of Post-stroke Depression |
title_sort | natural products for the treatment of post-stroke depression |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196125/ https://www.ncbi.nlm.nih.gov/pubmed/35712727 http://dx.doi.org/10.3389/fphar.2022.918531 |
work_keys_str_mv | AT fangchaoyou naturalproductsforthetreatmentofpoststrokedepression AT zhangzeyu naturalproductsforthetreatmentofpoststrokedepression AT xuhoushi naturalproductsforthetreatmentofpoststrokedepression AT liuyibo naturalproductsforthetreatmentofpoststrokedepression AT wangxiaoyu naturalproductsforthetreatmentofpoststrokedepression AT yuanling naturalproductsforthetreatmentofpoststrokedepression AT xuyuanzhi naturalproductsforthetreatmentofpoststrokedepression AT zhuzhengyang naturalproductsforthetreatmentofpoststrokedepression AT zhanganke naturalproductsforthetreatmentofpoststrokedepression AT shaoanwen naturalproductsforthetreatmentofpoststrokedepression AT loumeiqing naturalproductsforthetreatmentofpoststrokedepression |